HIV patients can choose: daily pill or Every-2-Month shot in new study

NCT ID NCT05917509

Ongoing Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 19 times

Summary

This study looks at two different HIV treatments for people who have never taken HIV medication before. Everyone starts with a daily pill (Dolutegravir/Lamivudine) to lower the virus to undetectable levels. Once that happens, participants can choose to either stay on the daily pill or switch to a long-acting shot (Cabotegravir plus Rilpivirine) given every two months. The goal is to see how well both options keep the virus under control and how patients feel about their treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Birmingham, Alabama, 35205, United States
GSK Investigational Site

Bakersfield, California, 93301, United States
GSK Investigational Site

Fort Lauderdale, Florida, 33308, United States
GSK Investigational Site

Ft. Pierce, Florida, 34982, United States
GSK Investigational Site

Orlando, Florida, 32804, United States
GSK Investigational Site

Pensacola, Florida, 32504, United States
GSK Investigational Site

Berkley, Michigan, 48072, United States
GSK Investigational Site

Kansas City, Missouri, 64111, United States
GSK Investigational Site

Omaha, Nebraska, 68198, United States
GSK Investigational Site

Henderson, Nevada, 89106, United States
GSK Investigational Site

Charlotte, North Carolina, 28204, United States
GSK Investigational Site

Huntersville, North Carolina, 28078, United States
GSK Investigational Site

Beaumont, Texas, 77701, United States
GSK Investigational Site

Dallas, Texas, 75246, United States
GSK Investigational Site

Fort Worth, Texas, 76104, United States
GSK Investigational Site

Buenos Aires, C1202, Argentina
GSK Investigational Site

Ciudad Autonoma de Bueno, 1405, Argentina
GSK Investigational Site

Mar del Plata, B7600DHK, Argentina
GSK Investigational Site

Rosario, S2013, Argentina
GSK Investigational Site

Hamilton, Ontario, L8S 1A4, Canada
GSK Investigational Site

Montreal, Quebec, H2L 4P9, Canada
GSK Investigational Site

La Cisterna, 7970000, Chile
GSK Investigational Site

Providencia, 7500000, Chile
GSK Investigational Site

Santiago, 9500000, Chile
GSK Investigational Site

Temuco, 4780000, Chile
GSK Investigational Site

Créteil, 94000, France
GSK Investigational Site

Orléans, 45067, France
GSK Investigational Site

Paris, 75004, France
GSK Investigational Site

Paris, 75015, France
GSK Investigational Site

Paris, 75475, France
GSK Investigational Site

Düsseldorf, 40225, Germany
GSK Investigational Site

Frankfurt am Main, 60329, Germany
GSK Investigational Site

Hamburg, 20246, Germany
GSK Investigational Site

München, 80337, Germany
GSK Investigational Site

Foggia, 71100, Italy
GSK Investigational Site

Milan, 20127, Italy
GSK Investigational Site

Milan, 20157, Italy
GSK Investigational Site

Roma, 00149, Italy
GSK Investigational Site

Ponce, 00717-1563, Puerto Rico
GSK Investigational Site

Almería, 04009, Spain
GSK Investigational Site

Granada, 35016, Spain
GSK Investigational Site

La Laguna-Tenerife, 35010, Spain
GSK Investigational Site

Madrid, 28007, Spain
GSK Investigational Site

Madrid, 28031, Spain
GSK Investigational Site

Málaga, 29010, Spain
GSK Investigational Site

Murcia, 30008, Spain
GSK Investigational Site

Seville, 41071, Spain

Conditions

Explore the condition pages connected to this study.

HIV INFECTIONS